Penn Medicine Provider
Hematology
Saar I. Gill, MD, PhD
4.9
(44)
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 4th Floor West
Make an appointmentCall 215-615-5858

About me

  • Scientific Co-Director, Cell Therapy and Transplant Program
  • Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania

Education and training

  • Medical School: University of Melbourne
  • Residency: St. Vincent's Hospital Melbourne
  • Residency: St. Vincent Hospital
  • Residency: St. Vincent's Hospital
  • null
  • Fellowship: Peter MacCallum Cancer Centre
  • null
  • Fellowship: Hospital of the University of Pennsylvania

What my patients think about me

Average Rating
4.9

44 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

April 2025
5.0
5.0
it was a great first time experience. the attention afforded to our situation was especially gratifying as it was taken into great consideration
March 2025
5.0
5.0
total confidence
January 2025
5.0
5.0
he's thorough and he listens
November 2024
5.0
5.0
relates well

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Gill is a Penn Medicine physician.

Qualifications and experience

My research

Bhagwat AS, Torres L, Shestova O, Shestov M, Mellors PW, Fisher HR, Farooki SN, Frost BF, Loken MR, Gaymon AL, Frazee D, Rogal W, Frey N, Hexner EO, Luger SM, Loren AW, Martin ME, McCurdy SR, Perl AE, Stadtmauer EA, Brogdon JL, Fraietta JA, Hwang WT, Siegel DL, Plesa G, Aplenc R, Porter DL, June CH, Gill SI. Cytokine-mediated CAR T therapy resistance in AML. , Nature Medicine, 30(12): 2024,3697-3708.

Wellhausen N, Gill S. CD45 threads the needle of cytokine cancer immunotherapy. , Nature Immunology, 25(10): 2024,1774-1777

Kang Y, Lefebvre B, Pamies IM, Gill SI, Doucette AG, Denduluri S, Smith AM, McCurdy S, Luger S, Carver J, Scherrer-Crosbie M. Symptomatic Heart Failure and Clonal Hematopoiesis-Related Mutations in Patients With Acute Myeloid Leukemia , Am Journal of Cardiology: 2024,1:226:9-17. doi: 10.1016/j.amjcard.2024.06.033.

Wellhausen N, Baek J, Gill SI, June CH. Enhancing cellular immunotherapies in cancer by engineering selective therapeutic resistance , Nature Reviews Cancer, 24(9): 2024,614-628.

Chang JF, Wellhausen N, Engel NW, Landmann JH, Hopkins CR, Salas-McKee J, Bear AS, Selli ME, Agarwal S, Jadlowsky JK, Linette GP, Gill S, June CH, Fraietta JA, Singh N. Identification of Core Techniques That Enhance Genome Editing of Human T Cells Expressing Synthetic Antigen Receptors , Cancer Immunology Research, 12(9): 2024,1136-1146.

Vinnakota JM, Biavasco F, Schwabenland M, Chhatbar C, Adams RC, Erny D, Duquesne S, El Khawanky N, Schmidt D, Fetsch V, Zähringer A, Salié H, Athanassopoulos D, Braun LM, Javorniczky NR, Ho JNHG, Kierdorf K, Marks R, Wäsch R, Simonetta F, Andrieux G, Pfeifer D, Monaco G, Capitini C, Fry TJ, Blank T, Blazar BR, Wagner E, Theobald M, Sommer C, Stelljes M, Reicherts C, Jeibmann A, Schittenhelm J, Monoranu CM, Rosenwald A, Kortüm M, Rasche L, Einsele H, Meyer PT, Brumberg J, Völkl S, Mackensen A, Coras R, von Bergwelt-Baildon M, Albert NL, Bartos LM, Brendel M, Holzgreve A, Mack M, Boerries M, Mackall CL, Duyster J, Henneke P, Priller J, Köhler N, Strübing F, Bengsch B, Ruella M, Subklewe M, von Baumgarten L, Gill S, Prinz M, Zeiser R. Targeting TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome , Nature Cancer, 5(8): 2024,1227-1249.

Gardner RA, White C, Elsallab M, Farnia S, Fraint E, Grilley B, Bateman-House A, Grupp SA, Kenderian S, Locke FL, Nikiforow S, Oluwole OO, Rouce RH, Spiegel J, Shah NN, Sharma A, Komanduri K, Gill S. ACT To Sustain: Adoptive Cell Therapy To Sustain Access to Non-Commercialized Genetically Modified Cell Therapies , Transplantation and Cell Therapy, 30(8): 2024,776-787

Connor MP, Prathapa N, Frey NV, Gill SI, Hexner EO, Bruno XJ, Lai CE, Loren AW, Luger SM, Matthews AH, McCurdy SR, Perl AE, Porter DL, Zeringue A, Oved JH, Olson TS, Pratz KW, Babushok DV. Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia , Haematologica, 109(8): 2024,2732-2737.

Veliz K, Shen F, Shestova O, Shestov M, Shestov A, Sleiman S, Hansen T, O'Connor RS, Gill S. Deletion of CD38 enhances CD19 chimeric antigen receptor T cell function. , Molecular Therapy Oncology, 32(2): 2024,200819.

Sung AD, Koll T, Gier SH, Racioppi A, White G, Lew M, Free M, Agarwal P, Bohannon LM, Johnson EJ, Selvan B, Babushok DV, Frey NV, Gill SI, Hexner EO, Martin M, Perl AE, Pratz KW, Luger SM, Chao NJ, Fisher AL, Stadtmauer EA, Porter DL, Loren AW, Bhatt VR, Gimotty PA, McCurdy SR. Preconditioning Frailty Phenotype Influences Survival and Relapse for Older Allogeneic Transplantation Recipients , Transplantation and Cell Therapy, 30(4): 2024,415.e1-415.e16.